For a month now, China’s medical products regulator has been negotiating with Pfizer to obtain the license to produce the antiviral drug Paxlovid in China. Beijing is fairly resistant to western treatments and vaccines, but Paxlovid is one of the foreign approved medicine. This medicine reduces hospitalization in high-risk patients by around 90%. That’s what the clinical trials showed. The Pfizer representative assured that the company actively cooperates with the authorities and all stakeholders to secure an adequate supply of Paxlovid in China. And Beijing seeks to finalize licensing terms before the Lunar New Year.